Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 06 Nov 2018 Planned End Date changed from 1 Sep 2006 to 5 Sep 2006.
- 30 Jun 2009 Primary endpoint identified as response rate as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.